UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Expert opinion on drug metabolism & toxicology, 2015, Vol.11 (8), p.1193-1201

2015

Volltextzugriff (PDF)

Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes

Diabetes (New York, N.Y.), 2004-06, Vol.53 (6), p.1614-1620

2004

Volltextzugriff (PDF)

Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose™)

British journal of nutrition, 2010-06, Vol.103 (12), p.1730-1737

2010

Volltextzugriff (PDF)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

Diabetes care, 2009-08, Vol.32 (8), p.1431-1433

2009

Volltextzugriff (PDF)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.208-215

2017

Volltextzugriff (PDF)

Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro

Diabetes care, 2005-10, Vol.28 (10), p.2400-2405

2005

Volltextzugriff (PDF)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Volltextzugriff (PDF)

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Journal of clinical pharmacology, 2015-05, Vol.55 (5), p.497-504

2015

Volltextzugriff (PDF)

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Diabetes technology & therapeutics, 2020-04, Vol.22 (4), p.278-284

2020

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Clinical pharmacokinetics, 2017-06, Vol.56 (6), p.649-660

2017

Volltextzugriff (PDF)

New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality

Journal of diabetes science and technology, 2022-03, Vol.16 (2), p.408-414

2022

Volltextzugriff (PDF)

Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion

Diabetes care, 2009-08, Vol.32 (8), p.1437-1439

2009

Volltextzugriff (PDF)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Clinical pharmacokinetics, 2020-12, Vol.59 (12), p.1601-1610

2020

Volltextzugriff (PDF)

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes

Journal of diabetes science and technology, 2018-01, Vol.12 (1), p.145-151

2018

Volltextzugriff (PDF)

Euglycaemic glucose clamp: what it can and cannot do, and how to do it

Diabetes, obesity & metabolism, 2016-10, Vol.18 (10), p.962-972

2016

Volltextzugriff (PDF)

A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes

Diabetes, obesity & metabolism, 2021-03, Vol.23 (3), p.674-681

2021

Volltextzugriff (PDF)

130-LB: Comparative PK and PD of the Rapid-Acting Insulin Aspart Product SAR341402, NovoLog, and NovoRapid in Subjects with T1D

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (URLi) and Lispro

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

Clinical drug investigation, 2017-05, Vol.37 (5), p.503-509

2017

Volltextzugriff (PDF)

Similar pharmacokinetics and pharmacodynamics of rapid‐acting insulin lispro products SAR342434 and US‐ and EU‐approved Humalog in subjects with type 1 diabetes

Diabetes, obesity & metabolism, 2017-05, Vol.19 (5), p.622-627

2017

Volltextzugriff (PDF)

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Diabetologia, 2016-04, Vol.59 (4), p.700-708

2016

Volltextzugriff (PDF)

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

Diabetes therapy, 2014-06, Vol.5 (1), p.255-265

2014

Volltextzugriff (PDF)

1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300U/mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Volltextzugriff (PDF)

Insulin degludec: L ower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(70)

Sprache

Englisch
(70)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Humans
(29)
Insulin
(25)
Male
(23)
Endocrinology & Metabolism
(21)
Adult
(20)
Middle Aged
(20)
Diabetes
(19)
Female
(17)
Diabetes Mellitus, Type 1 - Drug Therapy
(16)
Cross-Over Studies
(13)
Glucose
(13)
Glucose Clamp Technique
(13)
Diabetes Mellitus, Type 1 - Blood
(12)
Hypoglycemic Agents - Administration & Dosage
(12)
Pharmacokinetics
(12)
Double-Blind Method
(11)
Hypoglycemic Agents - Pharmacokinetics
(11)
Original
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes

Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose™)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial

Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality

Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes

Euglycaemic glucose clamp: what it can and cannot do, and how to do it

A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes

130-LB: Comparative PK and PD of the Rapid-Acting Insulin Aspart Product SAR341402, NovoLog, and NovoRapid in Subjects with T1D

105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (URLi) and Lispro

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

Similar pharmacokinetics and pharmacodynamics of rapid‐acting insulin lispro products SAR342434 and US‐ and EU‐approved Humalog in subjects with type 1 diabetes

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300U/mL in type 1 diabetes

Insulin degludec: L ower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetes

Suchergebnisse filtern